NJ Bio, Inc. and Ajinomoto Bio‑Pharma Services Enter into Collaboration to Strengthen Support for Antibody-Drug Conjugate Development

NJ Bio, Inc. and Ajinomoto Bio‑Pharma Services Enter into Collaboration to Strengthen Support for Antibody-Drug Conjugate Development

PRINCETON, N.J. and TOKYO, April 1, 2026 /PRNewswire/ -- NJ Bio, Inc. ("NJ Bio"), a leading provider of integrated drug discovery and development services and Ajinomoto Bio‑Pharma Services ("Aji Bio‑Pharma"), a leading provider of biopharmaceutical...

Samsung Biologics completes acquisition of GSK's manufacturing facility in Rockville, Maryland

Samsung Biologics completes acquisition of GSK's manufacturing facility in Rockville, Maryland

Adds 60,000 liters of drug substance capacity, bringing the total to 845,000 liters Marks Samsung Biologics' geographical diversification and establishes its first U.S. manufacturing presence, expanding regional client support Plans further...

Samsung Biologics Recognized for Advancing Sustainability at 2026 CDMO Leadership Awards

Samsung Biologics Recognized for Advancing Sustainability at 2026 CDMO Leadership Awards

Reinforcing long-term commitment to embedding sustainability across operations and partnerships Continuing to support clients in delivering high-quality, life-saving medicines to patients worldwide INCHEON, South Korea, March 26, 2026 /PRNewswire/...

Earendil Labs Enters Strategic Collaboration with WuXi XDC on WuXiTecan-2 Payload-Linker Technology Platform

Earendil Labs Enters Strategic Collaboration with WuXi XDC on WuXiTecan-2 Payload-Linker Technology Platform

WILMINGTON, Del., Feb. 27, 2026 /PRNewswire/ -- Earendil Labs, a global leader in AI-driven research and development of next-generation biologics therapeutics, today announced a strategic collaboration with WuXi XDC Cayman Inc. ("WuXi XDC", stock...

BIOSeedin Winter Innovation Partnering Summit:J.P.Morgan Spotlight

BIOSeedin Winter Innovation Partnering Summit:J.P.Morgan Spotlight

SAN FRANCISCO, Jan. 26, 2026 /PRNewswire/ -- To enable Chinese innovative pharmaceutical companies to more efficiently connect with international resources, bioSeedin, a platform facilitating cooperation in innovative drug assets, hosted the...

Celltrion presents innovative drug pipeline and U.S. manufacturing and R&D expansion strategy at the 44th Annual J.P. Morgan Healthcare Conference

Celltrion presents innovative drug pipeline and U.S. manufacturing and R&D expansion strategy at the 44th Annual J.P. Morgan Healthcare Conference

Celltrion outlines a blueprint for innovative drug development built on its antibody expertise The company highlights its business strategy to scale U.S. manufacturing and R&D capabilities, strengthening its global supply chain, production and...

Samsung Biologics recognized as a global leader in water security

Samsung Biologics recognized as a global leader in water security

Company receives the highest Water Security rating in two years into participation Recognized for exceptional leadership in environmental stewardship INCHEON, South Korea, Dec. 11, 2025 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a leading...

Harbour BioMed Advances Global Strategic Collaboration with AstraZeneca to Discover and Develop Next-Generation Biotherapeutics in Oncology

Harbour BioMed Advances Global Strategic Collaboration with AstraZeneca to Discover and Develop Next-Generation Biotherapeutics in Oncology

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Nov. 24, 2025 /PRNewswire/ -- Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics...

Ajinomoto Bio-Pharma Services Wins "Best ADC Preclinical Publication 2024" Award for AJICAP® Technology at 2025 World ADC Awards

Ajinomoto Bio-Pharma Services Wins "Best ADC Preclinical Publication 2024" Award for AJICAP® Technology at 2025 World ADC Awards

Recognition underscores Ajinomoto Bio-Pharma Services' innovation and scientific excellence in advancing next-generation antibody-drug conjugate technologies TOKYO, Nov. 17, 2025 /PRNewswire/ -- Ajinomoto Bio-Pharma Services ("Aji Bio-Pharma"), a...

Samsung Biologics completes spin-off to strengthen its focus as a pure-play CDMO

Samsung Biologics completes spin-off to strengthen its focus as a pure-play CDMO

Spin-off finalized within five months following board resolution Proposal approved in shareholders' meeting with 99.9% support Company to reaffirm its identity as a pure-play CDMO INCHEON, South Korea, Nov. 3, 2025 /PRNewswire/ -- Samsung Biologics...

  • 1
  • 2
  • menu
    menu